I argue that crossover should not be “allowed”- they should either be “mandated” or “prohibited” – Bishal Gyawali

Hot off the press in NatureRevClinOncol! Using examples from trials presented at ASCO23, in this educational piece, I highlight how we should think about crossover in cancer clinical trials. Such education also forms a core theme of what we do Common Sense Oncology. In this piece, I argue that crossover should not be “allowed”- they should either be “mandated” or “prohibited”.

For article : Click here

Source: Bishal Gyawali/Twitter